Plasma Rich in Growth Factors May Promote Hair Regeneration

This article originally appeared here.
Share this content:
Plasma Rich in Growth Factors May Promote Hair Regeneration
Plasma Rich in Growth Factors May Promote Hair Regeneration

WEDNESDAY, Nov. 22, 2017 (HealthDay News) -- Plasma rich in growth factors (PRGF) can minimize postsurgical follicle loss and promote hair regeneration in patients undergoing follicular unit extraction technique (FUE) for hair loss, according to a study published online Oct. 26 in the Journal of Cosmetic Dermatology.

Roge M. Navarro, M.D., from the Centro Dermatológico-Estético de Alicante in Spain, and colleagues examined the safety and clinical efficacy of PRGF technology as an adjuvant for FUE surgery in patients with hair loss. Fifteen patients were subjected to routine FUE and 15 underwent FUE + PRGF therapy. The PRGF group received intradermal injections of growth factors and follicular transfer unit (FTU) preservation in an autologous fibrin clot.

The researchers found that after treatment with autologous growth factors, follicular cell proliferation and migration was induced. Higher bioactivity signals and improved integrity of perifollicular structure and extracellular matrix proteins such as collagen and elastic fibers were presented with PRGF-preserved FTUs. Postsurgical crust healing and hair fixation period were reduced with PRGF, which also decreased the inflammatory pain and itching sensation.

"[These] preliminary data demonstrate that PRGF is able to minimize the postsurgical follicle loss and potentiate the performance of grafted hairs," the authors write. "The fibrin clot not only acts as a protective barrier against environmental factors, but also provides a biologically active scaffold that induces resident cell proliferation and maintains an optimal integrity of the grafted hair."

Several authors are employees of the BTI Biotechnology Institute, which developed the PRGF-Endoret technology.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »